Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP)

D. Wolf, S. Mustjoki, B. -T Gjertsen, G. Gastl, M. Baldauf, Z. Trajanoski, F. Giles, A. Hochhaus, T. Ernst, T. Schenk, J. Janssen, K. Porkka, S. Sopper

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)39-39
JournalONCOLOGY RESEARCH AND TREATMENT
Volume39
Publication statusPublished - Oct 2016

Cite this

Wolf, D., Mustjoki, S., Gjertsen, B. -T., Gastl, G., Baldauf, M., Trajanoski, Z., ... Sopper, S. (2016). Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP). ONCOLOGY RESEARCH AND TREATMENT, 39, 39-39.